BridgeBio Oncology Therapeutics, Inc. (BBOT) Operating cash flow 2024–2025
BridgeBio Oncology Therapeutics, Inc. (BBOT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$113.9MFY2025 · since FY2024: -$55.0M → -$113.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$113.9M | -107.0% |
| FY2024 | -$55.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBOT financial trends
BBOT RevenueBBOT Net incomeBBOT Net marginBBOT Gross profitBBOT Gross marginBBOT Operating incomeBBOT Operating marginBBOT Free cash flowBBOT Capital expendituresBBOT Return on equityBBOT Stock buybacksBBOT Dividends paidBBOT Total assetsBBOT Total liabilitiesBBOT Shareholders’ equityBBOT overview →